Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance

James L. Mulshine, Bruce E. Johnson, Adi F. Gazdar, Gail L. Shaw, Barnett S. Kramer, Tetsuya Mitsudomi, John D. Minna, Harvey Pass, Ruby Phelps, Bimal Ghosh, R. Ilona Linnoila, Daniel C. Ihde

Research output: Contribution to journalArticlepeer-review


Consideration of a range of clinical and basic studies conducted at the National Cancer Institute which explore the nature of the tumor biology of lung identify the limitations of using chemotherapy for the treatment of advanced lung cancer. No single mechanistic explanation for lung cancer's chemoresistance is apparent, although considerable information about the biology of lung cancer and some of its clinical consequences have been elucidated. In contrast to previous works from our group, this presentation will focus principally on studies of the nature of drug resistance with non-small cell cancer. An alternative combined modality strategy for lung cancer control is to focus on epithelial progression of lung cancer using local modalities while it is still confined to the bronchial epithelium. Particular high risk populations may be appropriate to determine if local tools such as photodynamic laser therapy can be effective in this application. To deal with the underlying biochemical perturbations resulting from critical exposure of the bronchial epithelium to carcinogens, rational biochemical intervention with 13 cis retinoic acid are being evaluated in several clinical trials. An evolution towards more effective lung cancer.

Original languageEnglish (US)
Pages (from-to)S73-S81
JournalLung Cancer
Issue numberSUPPL. 1
StatePublished - Mar 1994

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance'. Together they form a unique fingerprint.

Cite this